{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:10:18Z","timestamp":1779095418868,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.survophthal.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:28:12Z","timestamp":1771054092000},"page":"1029-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of anti-vascular endothelial growth factor (VEGF) plus corticosteroids versus anti-VEGF alone for macular edema from retinal vein occlusion: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9053-7663","authenticated-orcid":false,"given":"Maryum","family":"Khilji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Hira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeeshan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahroz","family":"Ansar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Ahmed","family":"Idrees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wadana","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunger Yar","family":"Rekham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshmaan","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faris","family":"Fayyaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryum","family":"Amyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Samra","family":"Batool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Tehseen","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo Bolzani","family":"Bach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib1","first-page":"40","article-title":"Retinal vein occlusion review","volume":"7","author":"Ip","year":"2018","journal-title":"Asia Pac J Ophthalmol [Internet]"},{"issue":"2","key":"10.1016\/j.survophthal.2026.02.004_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/APO.0000000000000598","article-title":"Update on retinal vein occlusion","volume":"12","author":"Romano","year":"2023","journal-title":"Asia Pac J Ophthalmol [Internet]"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib3","article-title":"Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors","volume":"9","author":"Song","year":"2019","journal-title":"J Glob Health [Internet]"},{"key":"10.1016\/j.survophthal.2026.02.004_bib4","doi-asserted-by":"crossref","unstructured":"Jonas J., Paques M., Mon\u00e9s J., Glacet-Bernard A. Retinal vein occlusions. In: Coscas G, Cunha-Vaz J, Loewenstein A, Soubrane G, editors. Macular Edema: A Practical Approach. S.Karger AG; 2010. p. 111\u201335. doi:\u300810.1159\/000320076\u3009.","DOI":"10.1159\/000320076"},{"issue":"5","key":"10.1016\/j.survophthal.2026.02.004_bib5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/archopht.126.5.692","article-title":"Retinal vein occlusion and traditional risk factors for atherosclerosis","volume":"126","author":"O\u2019Mahoney","year":"2008","journal-title":"Arch Ophthalmol [Internet]"},{"issue":"2","key":"10.1016\/j.survophthal.2026.02.004_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmol [Internet]"},{"issue":"7","key":"10.1016\/j.survophthal.2026.02.004_bib7","article-title":"Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion","author":"Shalchi","year":"2020","journal-title":"Cochrane Database Syst Rev [Internet]"},{"issue":"3","key":"10.1016\/j.survophthal.2026.02.004_bib8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1573399811666150615151324","article-title":"Anti-VEGF therapy for retinal vein occlusions","volume":"17","author":"Campa","year":"2016","journal-title":"Curr Drug Targets"},{"issue":"3","key":"10.1016\/j.survophthal.2026.02.004_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion","volume":"98","author":"Group TBVOS","year":"1984","journal-title":"Am J Ophthalmol [Internet]"},{"issue":"6","key":"10.1016\/j.survophthal.2026.02.004_bib10","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2026.02.004_bib11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion (SCORE) study report 6","volume":"127","author":"Scott","year":"2009","journal-title":"Arch Ophthalmol [Internet]"},{"issue":"3","key":"10.1016\/j.survophthal.2026.02.004_bib12","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","article-title":"Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab","volume":"50","author":"Funk","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.survophthal.2026.02.004_bib13","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmol [Internet]"},{"issue":"3","key":"10.1016\/j.survophthal.2026.02.004_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000502041","article-title":"Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)","volume":"242","author":"Schmidt-Erfurth","year":"2019","journal-title":"Opthalmologica [Internet"},{"key":"10.1016\/j.survophthal.2026.02.004_bib15","article-title":"Increased intraocular inflammation in retinal vein occlusion is independent of circulating immune mediators and is involved in retinal oedema","volume":"17","author":"Zhou","year":"2023","journal-title":"Front Neurosci [Internet]"},{"issue":"2","key":"10.1016\/j.survophthal.2026.02.004_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/2013.jamaophthalmol.228","article-title":"Association of inflammatory factors with macular edema in branch retinal vein occlusion","volume":"131","author":"Noma","year":"2013","journal-title":"JAMA Ophthalmol [Internet]"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.18008\/1816-5095-2019-1-95-101","article-title":"The role of steroids in the management of macular edema from retinal vein occlusion","volume":"16","author":"Budzinskaya","year":"2019","journal-title":"Ophthalmol Russ [Internet]"},{"issue":"4","key":"10.1016\/j.survophthal.2026.02.004_bib18","first-page":"P313","article-title":"Retinal Vein Occlusions Preferred Practice Pattern\u00ae","volume":"132","author":"Kovach","year":"2025","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib19","first-page":"4","article-title":"Simultaneous therapy with intravitreal dexamethasone implant and bevacizumab for the treatment of macular edema","volume":"5","author":"de Andrade","year":"2016","journal-title":"Med Hypothesis Discov Innov Ophthalmol [Internet]"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/08820538.2023.2249527","article-title":"Intravitreal Injection of anti-vascular endothelial growth factors combined with corticosteroids for the treatment of macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis","volume":"39","author":"Namvar","year":"2024","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12886-022-02682-7","article-title":"Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Ophthalmol [Internet]"},{"key":"10.1016\/j.survophthal.2026.02.004_bib22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ [Internet]"},{"key":"10.1016\/j.survophthal.2026.02.004_bib23","series-title":"Cochrane Handbook for Systematic Reviews of Interventions [Internet]","author":"Higgins","year":"2019"},{"key":"10.1016\/j.survophthal.2026.02.004_bib24","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ [Internet]"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"7650","key":"10.1016\/j.survophthal.2026.02.004_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ [Internet]"},{"key":"10.1016\/j.survophthal.2026.02.004_bib27","unstructured":"Drahota A., Beller E. RevMan Calculator [Internet]. Available from: \u3008https:\/\/training.cochrane.org\/resource\/revman-calculator\u3009."},{"issue":"10","key":"10.1016\/j.survophthal.2026.02.004_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3109\/02713683.2010.496540","article-title":"A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion","volume":"35","author":"\u00c7eki\u00e7","year":"2010","journal-title":"Curr Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib29","first-page":"89","article-title":"Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion","volume":"4","author":"Wang","year":"2011","journal-title":"Int J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2026.02.004_bib30","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3109\/02713683.2014.885533","article-title":"Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion","volume":"39","author":"Fan","year":"2014","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2026.02.004_bib31","first-page":"1057","article-title":"A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion","volume":"8","author":"Maturi","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib32","first-page":"98","article-title":"Intravitreal injection with ranibizumab combined with triamcinolone acetonide sub-tenon injection for macular edema due to CRVO","volume":"15","author":"Li","year":"2015","journal-title":"Int Eye Sci [Internet]"},{"issue":"8","key":"10.1016\/j.survophthal.2026.02.004_bib33","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/eye.2016.96","article-title":"Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion","volume":"30","author":"Moon","year":"2016","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.survophthal.2026.02.004_bib34","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.19082\/5068","article-title":"Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: a randomized clinical trial","volume":"9","author":"Motarjemizadeh","year":"2017","journal-title":"Electron Physician"},{"key":"10.1016\/j.survophthal.2026.02.004_bib35","unstructured":"Csaky K. Effect of Ozurdex\u00ae 0.7 mg on improvement of efficacy of bevacizumab for central retinal vein occlusion [Internet]. [cited 2025 Jul 12]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01295112."},{"issue":"4","key":"10.1016\/j.survophthal.2026.02.004_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the Tanzanite study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"10.1016\/j.survophthal.2026.02.004_bib37","first-page":"569","article-title":"Combined treatment with bevacizumab and triamcinolone acetonide for macular edema due to retinal vein occlusion","volume":"59","author":"Vinkovi\u0107","year":"2020","journal-title":"Acta Clin Croat [Internet]"},{"key":"10.1016\/j.survophthal.2026.02.004_bib38","unstructured":"Clearside Biomedical Inc. Suprachoroidal injection of triamcinolone acetonide with IVT aflibercept in subjects with macular edema following RVO (SAPPHIRE) [Internet]. [cited 2025 May 31]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT02980874\u3009."},{"key":"10.1016\/j.survophthal.2026.02.004_bib39","unstructured":"Clearside Biomedical Inc. Suprachoroidal injection of triamcinolone acetonide with IVT anti-VEGF in subjects with macular edema following RVO (TOPAZ) [Internet]. [cited 2025 May 31]. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03203447\u3009."},{"key":"10.1016\/j.survophthal.2026.02.004_bib40","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/OPTH.S361636","article-title":"Modified microneedle for suprachoroidal injection of triamcinolone acetonide combined with intravitreal injection of ranibizumab in branch retinal vein occlusion patients","volume":"16","author":"Nawar","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2026.02.004_bib41","first-page":"1717","article-title":"Efficacy of dexamethasone intravitreal implant combined with anti-VEGF drug in the treatment of retinal vein occlusion","volume":"22","author":"Wang","year":"2022","journal-title":"Int Eye Sci [Internet]"},{"issue":"2","key":"10.1016\/j.survophthal.2026.02.004_bib42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/jop.2021.0100","article-title":"Add-on effect of simultaneous intravitreal dexamethasone to intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion","volume":"38","author":"Limon","year":"2022","journal-title":"J Ocul Pharm Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib43","first-page":"117","article-title":"Combination of ranibizumab and dexamethasone intravitreal implant for macular edema secondary to retinal vein occlusion","volume":"24","author":"Zhu","year":"2024","journal-title":"Int Eye Sci [Internet]"},{"issue":"5","key":"10.1016\/j.survophthal.2026.02.004_bib44","first-page":"1778","article-title":"Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion","volume":"16","author":"Anand","year":"2024","journal-title":"IJPCR [Internet]"},{"issue":"4","key":"10.1016\/j.survophthal.2026.02.004_bib45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/0115748871315894240514044305","article-title":"Safety and efficiency of anti-VEGF with dexamethasone intravitreal implant for non-ischemic retinal vein occlusion: a prospective, case-controlled, cohort study","volume":"19","author":"Cai","year":"2024","journal-title":"Rev Recent Clin Trials"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10792-024-03158-x","article-title":"Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial","volume":"44","author":"Meng","year":"2024","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.02.004_bib47","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/OPTH.S448671","article-title":"Intravitreal injection of conbercept combined with dexamethasone for macular edema following central retinal vein occlusion","volume":"18","author":"Wu","year":"2024","journal-title":"Clin Ophthalmol [Internet]"},{"issue":"7","key":"10.1016\/j.survophthal.2026.02.004_bib48","first-page":"1289","article-title":"Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion","volume":"32","author":"Singer","year":"2012","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ophtha.2008.09.034","article-title":"Vitreous Levels of Interleukin-6 and Vascular Endothelial Growth Factor in Macular Edema with Central Retinal Vein Occlusion","volume":"116","author":"Noma","year":"2009","journal-title":"Ophthalmol [Internet]"},{"issue":"1","key":"10.1016\/j.survophthal.2026.02.004_bib50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2415-13-78","article-title":"Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series","volume":"13","author":"Noma","year":"2013","journal-title":"BMC Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2026.02.004_bib51","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.3390\/jcm9113457","article-title":"Cytokines and Pathogenesis of Central Retinal Vein Occlusion","volume":"9","author":"Noma","year":"2020","journal-title":"J Clin Med"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:42:10Z","timestamp":1779093730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726000184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0039625726000184"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.02.004","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of anti-vascular endothelial growth factor (VEGF) plus corticosteroids versus anti-VEGF alone for macular edema from retinal vein occlusion: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}